MX2022005330A - Moleculas de union multiespecificas con scfv en el extremo nterminal. - Google Patents
Moleculas de union multiespecificas con scfv en el extremo nterminal.Info
- Publication number
- MX2022005330A MX2022005330A MX2022005330A MX2022005330A MX2022005330A MX 2022005330 A MX2022005330 A MX 2022005330A MX 2022005330 A MX2022005330 A MX 2022005330A MX 2022005330 A MX2022005330 A MX 2022005330A MX 2022005330 A MX2022005330 A MX 2022005330A
- Authority
- MX
- Mexico
- Prior art keywords
- mbms
- binding molecules
- multispecific binding
- terminal scfv
- mbm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Moléculas de unión multiespecíficas (MBM) que comprenden un scFv en el extremo N-terminal, un primer Fab y un segundo Fab, conjugados de MBM que comprenden las MBM y agentes citotóxicos o citostáticos, composiciones farmacéuticas que contienen las MBM y conjugados de MBM, métodos para usar las MBM, conjugados de MBM y composiciones farmacéuticas para tratar el cáncer, ácidos nucleicos que codifican las MBM, células modificadas genéticamente para expresar las MBM y métodos para producir las MBM.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962930916P | 2019-11-05 | 2019-11-05 | |
PCT/US2020/058798 WO2021091953A1 (en) | 2019-11-05 | 2020-11-04 | N-terminal scfv multispecific binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005330A true MX2022005330A (es) | 2022-05-26 |
Family
ID=73598993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005330A MX2022005330A (es) | 2019-11-05 | 2020-11-04 | Moleculas de union multiespecificas con scfv en el extremo nterminal. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210130477A1 (es) |
EP (1) | EP4054646A1 (es) |
JP (1) | JP2022553830A (es) |
KR (1) | KR20220093363A (es) |
CN (1) | CN114786730A (es) |
AU (1) | AU2020379735A1 (es) |
BR (1) | BR112022008552A2 (es) |
CA (1) | CA3157075A1 (es) |
IL (1) | IL292698A (es) |
MX (1) | MX2022005330A (es) |
TW (1) | TW202134277A (es) |
WO (1) | WO2021091953A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210130477A1 (en) * | 2019-11-05 | 2021-05-06 | Regeneron Pharmaceuticals, Inc. | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES |
KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
BR112023022878A2 (pt) * | 2021-05-04 | 2024-01-23 | Regeneron Pharma | Agonistas do receptor fgf21 multiespecíficos e seus usos |
CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
WO2024152014A1 (en) * | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE151113T1 (de) | 1992-01-23 | 1997-04-15 | Merck Patent Gmbh | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
ES2457538T3 (es) | 2003-02-20 | 2014-04-28 | Seattle Genetics, Inc. | Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
TWI544076B (zh) | 2005-03-31 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | A method of manufacturing a polypeptide that controls assembly |
WO2007011968A2 (en) | 2005-07-18 | 2007-01-25 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
MX345909B (es) * | 2009-03-25 | 2017-02-22 | Genentech Inc | Anticuerpos anti-fgfr3 y métodos que los utilizan. |
WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
EP2511718B1 (en) | 2009-12-07 | 2017-07-05 | Ntt Docomo, Inc. | Propagation path estimation method, program, and device |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
WO2013096901A1 (en) | 2011-12-23 | 2013-06-27 | Mersana Therapeutics, Inc. | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
US10077298B2 (en) | 2012-11-28 | 2018-09-18 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
WO2014150973A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
AU2015236073B2 (en) * | 2014-03-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | FGF21 receptor agonists and uses thereof |
WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
AU2016289480C1 (en) * | 2015-07-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
WO2017134197A1 (en) * | 2016-02-05 | 2017-08-10 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
CN109476732B (zh) * | 2016-04-13 | 2024-03-22 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
US10793632B2 (en) * | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
NZ760232A (en) * | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
CN112074538A (zh) * | 2018-04-30 | 2020-12-11 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
US20210130477A1 (en) * | 2019-11-05 | 2021-05-06 | Regeneron Pharmaceuticals, Inc. | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES |
-
2020
- 2020-11-04 US US17/088,918 patent/US20210130477A1/en active Pending
- 2020-11-04 TW TW109138450A patent/TW202134277A/zh unknown
- 2020-11-04 JP JP2022525837A patent/JP2022553830A/ja active Pending
- 2020-11-04 KR KR1020227018857A patent/KR20220093363A/ko unknown
- 2020-11-04 CA CA3157075A patent/CA3157075A1/en active Pending
- 2020-11-04 BR BR112022008552A patent/BR112022008552A2/pt unknown
- 2020-11-04 EP EP20816036.6A patent/EP4054646A1/en active Pending
- 2020-11-04 WO PCT/US2020/058798 patent/WO2021091953A1/en unknown
- 2020-11-04 AU AU2020379735A patent/AU2020379735A1/en active Pending
- 2020-11-04 CN CN202080076958.2A patent/CN114786730A/zh active Pending
- 2020-11-04 MX MX2022005330A patent/MX2022005330A/es unknown
-
2022
- 2022-04-22 US US17/726,950 patent/US20220251220A1/en active Pending
- 2022-05-02 IL IL292698A patent/IL292698A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210130477A1 (en) | 2021-05-06 |
KR20220093363A (ko) | 2022-07-05 |
CN114786730A (zh) | 2022-07-22 |
AU2020379735A1 (en) | 2022-05-26 |
CA3157075A1 (en) | 2021-05-14 |
EP4054646A1 (en) | 2022-09-14 |
WO2021091953A1 (en) | 2021-05-14 |
IL292698A (en) | 2022-07-01 |
US20220251220A1 (en) | 2022-08-11 |
JP2022553830A (ja) | 2022-12-26 |
TW202134277A (zh) | 2021-09-16 |
BR112022008552A2 (pt) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
PH12018500520A1 (en) | Cd3 binding polypeptides | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
EP3882270A3 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
MX2024007140A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
MA32140B1 (fr) | Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens | |
MY178160A (en) | Anti-egfrviii antibodies and uses thereof | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
ZA201905462B (en) | Proteins binding her2, nkg2d and cd16 | |
MX2022001682A (es) | Nuevos formatos de moleculas de union a antigenos. | |
MX2023002945A (es) | Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas. | |
BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
AU2020380603A8 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
ATE466079T1 (de) | Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs | |
BR112022024833A2 (pt) | Conjugados anticorpo anti-bcma-fármaco e métodos de uso | |
MX2022012092A (es) | Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos. | |
SG11201910113PA (en) | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
MX2023013995A (es) | Conjugados de anticuerpo y antraciclina. |